Tibet Duo Rui Pharmaceutical Co., Ltd. Class A

Tibet Duo Rui Pharmaceutical Co., Ltd. Class A

SSZSE:301075
42.02
CNY
-1.01
(-2.35%)
-0.26EPS
5.05BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
14.29
4.36
5.62
8.15
8.12
5.09
4.26
3.03
1.95
2.1
Basic EPS, GAAP
2.48
0.54
0.9
1.53
1.05
0.26
0.24
-0.79
-1.29
-0.18
Free Cash Flow per Basic Share
4.79
0.63
0.28
0.21
0.66
-0.4
-0.14
-1.36
-1.86
- -
Dividend per Share
- -
- -
0.03
0.03
0.02
0.64
0.04
0.22
0.11
0.07
Book Value per Share
-0.06
1.86
3.7
4.04
9.91
9.39
9.65
8.46
7.18
8.21
Tangible Book Value per Share
-1.41
1.53
3.38
3.75
9.7
9.13
9.18
7.24
5.99
7.22
Basic Weighted Avg Shares
10
80
80
60
65
79
79
79
79
79
Sales/Revenue/Turnover
143
349
449
490
530
401
334
241
154
166
Operating Margin (%)
22.95
16.18
18.56
21.43
14.19
4.13
3.57
-29.36
-61.3
-27.12
Depreciation Expense
5
6
10
12
15
16
19
29
52
- -
Net Income, GAAP
25
43
72
92
69
21
19
-63
-102
-14
Effective Tax Rate (%)
6.83
19.01
11.6
11.29
10.12
11.61
23.18
- -
- -
- -
Profit Margin (%)
17.37
12.42
15.95
18.77
12.94
5.11
5.64
-26.04
-66.27
-8.35
Working Capital
-87
-21
54
107
666
503
520
121
-113
-119
LT Debt
- -
- -
- -
1
- -
1
118
145
92
2
Total Equity
-1
75
150
241
789
753
822
753
624
695
Return on Invested Capital (%)
- -
124.84
61.75
41.23
12.24
2.26
1.84
- -
- -
- -
Return on Capital (%)
- -
137.12
63.21
43.79
13.29
2.84
2.48
- -
- -
- -
Return on Common Equity (%)
- -
- -
63.85
46.85
13.23
2.65
2.47
-8.65
-16.33
-2.15

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
167
189
206
LT Borrowings
89
- -
- -
LT Finance Leases
4
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
80
80
80
Market Capitalization
4,976
4,561
5,054

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
330
322
528
Cash, Cash Equivalents & STI
65
65
303
Accounts Receivable, Net
99
101
81
Inventories
100
108
109
Total Current Liabilities
451
487
646
Payables & Accruals
- -
- -
- -
ST Debt
167
189
206
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
41.33%
-17.24%
Free Cash Flow
- -
178.21%
36.59%
Net Income, GAAP
- -
-94.61%
63.04%
Sales/Revenue/Turnover
- -
-19.36%
-35.93%
Total Cash Common Dividend
- -
909.1%
-48.53%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
78
72
50
40
241
2025
49
57
- -
17
154
2026
32
63
53
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
-0.01
-0.17
-0.58
-0.79
2025
-0.2
-0.34
- -
-0.28
-1.29
2026
-0.18
0.32
-0.04
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.14
0.02
0.03
0.22
2025
0.03
0.03
- -
0.02
0.11
2026
0.02
0.01
0.01
- -
- -

Company Description

CEO
Yong Deng
Full Time Employees
461
Sector
Health technology
Industry
Pharmaceuticals: generic
Address
Changdu China
IPO Date
Sep 29, 2021
Business
Tibet Duo Rui Pharmaceutical Co., Ltd. is a China-based pharmaceutical enterprise engaged in the research, development, manufacturing, and commercialization of chemical pharmaceutical preparations, active pharmaceutical ingredients (APIs), chemical intermediates, and traditional Chinese medicine formulations. The company operates primarily across pharmaceutical manufacturing and biotechnology segments, serving hospitals, medical centers, and life sciences clients across domestic and international markets. Its commercial and development product portfolio is categorized into: parenteral solutions and fluid balance therapies, featuring its flagship sodium acetate Ringer's injection for electrolyte regulation and acidosis correction, compound electrolyte injections, and compound mannitol injections; specialized clinical formulations for intensive care, anesthesia, and analgesia; peptide active pharmaceutical ingredients and therapeutic peptides, including lanreotide acetate, semaglutide, teriparatide, and tirzepatide; proprietary Chinese medicine formulations, including Yifei Jisheng granules; and contract development and manufacturing organization (CDMO) as well as custom synthesis services for biopharmaceutical developers. Founded in 2016 and headquartered in Qamdo, Tibet Autonomous Region, China, the company maintains research, administrative, and manufacturing facilities across regional centers in China, including advanced peptide API synthesis and formulation facilities in Sichuan Province. In recent strategic developments, the company expanded its upstream biotechnology value chain through the acquisition of Sichuan Frontier Biopharmaceutical Co., Ltd. (rebranded as Sichuan Duorui Pharmaceutical Co., Ltd.), establishing a high-end peptide API development and industrialization base focused on metabolic and therapeutic peptide pipelines. Additionally, the company completed a major ownership and management transition resulting in a change of actual control to a leadership consortium comprising Wang Qingtai, Cui Zihao, and Cao Xiaobing to drive operational modernization, alongside an internal asset optimization program that included the divestment and restructuring of non-core subsidiary assets such as Hubei Duorui Pharmaceutical Co., Ltd. to focus resources on core formulation competitiveness and advanced peptide API manufacturing.